BD Drives the Future of Immunology Research with Expanded Offerings for Simultaneous RNA and Protein Expression Analysis
FRANKLIN LAKES, N.J., July 26, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial release of the BD® AbSeq assay to analyze protein expression at the single-cell level using high-throughput sequencing. The assay brings together high-quality antibodies from the BD Pharmingen™ portfolio with oligonucleotides,... Read more